Metabolex, Warner-Lambert In $50 M Diabetes Deal | GenomeWeb

HAYWARD, Calif.--Metabolex, a privately held development-stage pharmaceutical company here, announced its second collaboration agreement with Warner-Lambert in diabetes research. The new deal is a five-year collaboration that will use genomics to discover and develop new therapeutics that treat type-2 diabetes by counteracting insulin resistance. Payments to Metabolex prior to commercialization could exceed $50 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.